US 12,290,560 B2
Vaccine for preventing or treating congenital infection with cytomegalovirus
Masaharu Torikai, Kumamoto (JP); Hiroaki Mori, Kumamoto (JP); Tomohiro Nishimura, Kumamoto (JP); Takahiro Katayama, Kanagawa (JP); Kohsuke Hazeyama, Kumamoto (JP); Miyuki Matsumoto, Kumamoto (JP); Hiroyuki Shimizu, Saitama (JP); and Naoki Inoue, Gifu (JP)
Assigned to KM Biologics Co., Ltd., Kumamoto (JP)
Appl. No. 17/312,235
Filed by KM Biologics Co., Ltd., Kumamoto (JP)
PCT Filed Dec. 6, 2019, PCT No. PCT/JP2019/047966
§ 371(c)(1), (2) Date Jun. 9, 2021,
PCT Pub. No. WO2020/121983, PCT Pub. Date Jun. 18, 2020.
Claims priority of application No. 2018-230640 (JP), filed on Dec. 10, 2018.
Prior Publication US 2022/0023416 A1, Jan. 27, 2022
Int. Cl. A61K 39/245 (2006.01); A61P 31/20 (2006.01); C12N 7/00 (2006.01); A61K 39/00 (2006.01)
CPC A61K 39/245 (2013.01) [A61P 31/20 (2018.01); C12N 7/00 (2013.01); A61K 2039/552 (2013.01)] 4 Claims
OG exemplary drawing
 
1. A method of preventing or treating congenital infection with HCMV in a subject, comprising administering a vaccine which comprises a modified human cytomegalovirus (HCMV) envelope glycoprotein B (gB protein) antigen and a pentamer antigen consisting of HCMV gH, gL, UL128, UL130, and UL131 to the subject, wherein the gB protein antigen is an HCMV gB protein ectodomain variant comprising the amino acid substitutions at positions 156, 157, 239, 240, 456, and 458 in the amino acid sequence set forth in SEQ ID NO:7.